We recently compiled a list of the Blackrock’s 30 Most Important AI Stocks. In this article, we are going to take a look at ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.